In lupus the CAR-T cells are modified not to target cancer, but instead a different type of immune cell called the B cell.

18 years of age or older diagnosed with SLE for at least 6 months currently taking medication to treat SLE currently experiencing disease-related symptoms * The study team can discuss with you any ...

This explains why IFN-I blocking therapies are more efficient to treat active skin disease in SLE. Healio: To that point, you learned that IFN-1, 2 and 3 fluctuate over time.

It does not involve any new patient allocation or masking. The primary purpose is to gather real-world evidence of anifrolumab’s effectiveness in managing SLE symptoms over time.

Highlighted below are several findings from the survey. SLE symptoms Roughly 60 percent of patients and 63 percent of physicians agree that patients have difficulty describing their symptoms.

Lupus can cause a wide range of symptoms, potentially affecting your oral health, including your teeth and gums. Lupus, or systemic lupus erythematosus (SLE), is an autoimmune disease where the ...

June 18, 2007 (Barcelona) — Patients with systemic lupus erythematosus (SLE) show a response in key measurements of disease activity when treated with belimumab ( LymphoStat-B, Human Genome ...